Skip to main content
Tesa Source

A chiaroscuro reading of the tesamorelin literature — the pharmacokinetics drawn into the light: a peptide that clears the plasma in minutes while its IGF-1 signal lingers across the day.

Match each claim to its paper

Tesamorelin References: which paper supports each claim?

Tesamorelin studies mainly followed people with HIV and unusual fat gain. Here you can find every paper, review, date, and 2026 result.

Return to the blood-time answerRead what the studies found

How can you find the right tesamorelin paper?

This man-made drug, tesamorelin, prompts natural growth hormone. The page helps you match a claim with its paper. The first two entries are Phase 3 studies, the large tests before approval. They followed people with HIV and unusual belly fat. A smaller dose study and the liver-fat study come next.

Other papers followed healthy men and measured growth hormone, blood sugar, or time in blood. One rat study examined damaged heart tissue. Reviews discuss liver scars and drug safety. In 2026, one review combined five trials and looked for the overall result. Combining them gives more people to judge and keeps one small trial from carrying the whole answer. The list also includes sports testing and work on saving muscle during weight loss.

Each entry names whether people or animals were studied and offers a public link when available. You can check the claim yourself or bring the paper to your doctor.

References cited

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  5. Tesamorelin - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2018. (Notes US approval in 2010, NDA 022505, for HIV-associated lipodystrophy; likelihood score E.) ↗
  6. Makimura H, Stanley TL, Chen CY, Branch KL, Grinspoon SK. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. Growth Horm IGF Res. 2011;21(3):155-159. ↗
  7. Falutz J, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287. ↗
  8. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-294. ↗
  9. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. ↗
  10. Kanashiro-Takeuchi RM, Takeuchi LM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 2012;109(2):559-563. ↗
  11. Yen DW, Sherman KE. Causes and outcomes of hepatic fibrosis in persons living with HIV. Curr Opin HIV AIDS. 2022;17(6):359-367. ↗
  12. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. ↗
  13. Ucakturk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal. 2026;254:117207. ↗
  14. Arora G, Conde KR, Desouza CV. Pharmacologic treatments for the preservation of lean body mass during weight loss. J Clin Med. 2026;15(2):541. ↗
  15. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. ↗